Abstract
Neurodegenerative disorders are devastating human diseases that include Parkinsons, Huntingtons, Alzheimers, amyotrophic lateral sclerosis, and the frontal temporal dementias. Although the clinical manifestations of these disorders have been known for quite some time, our understanding of the molecular underpinnings is only starting to emerge. Protein misfolding and aggregation is a common hallmark among these diseases, and produce a number of cellular and functional alterations. The loss of dopaminergic neurons in the substantia nigra justified the use of dopaminergic therapies in patients. However, these strategies do not appear to confer disease-modifying effects, and do not prevent progression. The idea that neurotrophic factors might promote cell survival is an attractive one. Existing evidence from clinical trials is currently inconclusive, but some patients display clear clinical benefits. Thus, the current challenge is to develop novel strategies that make the use of neurotrophic factors more consistent.
Keywords: Parkinson's disease, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, glial cell line derived neurotrophic factor, se, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontal temporal dementias, parkinsonism, BDNF, GDNF, NGF, (MAPK) pathway, neurturin, neublastin, enovin, persephin, (PSPN), TrK-mediated neurotrophin signaling, hyponatremia, Unified Parkinson's Disease Rating Scale, UPDRS, dyskinesias, L-Dopa-induced dyskinesias
CNS & Neurological Disorders - Drug Targets
Title: Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
Volume: 9 Issue: 6
Author(s): Maria Jose Diogenes and Tiago Fleming Outeiro
Affiliation:
Keywords: Parkinson's disease, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, glial cell line derived neurotrophic factor, se, protein misfolding, neurodegeneration, neurotrophins, brain-derived neurotrophic factor, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontal temporal dementias, parkinsonism, BDNF, GDNF, NGF, (MAPK) pathway, neurturin, neublastin, enovin, persephin, (PSPN), TrK-mediated neurotrophin signaling, hyponatremia, Unified Parkinson's Disease Rating Scale, UPDRS, dyskinesias, L-Dopa-induced dyskinesias
Abstract: Neurodegenerative disorders are devastating human diseases that include Parkinsons, Huntingtons, Alzheimers, amyotrophic lateral sclerosis, and the frontal temporal dementias. Although the clinical manifestations of these disorders have been known for quite some time, our understanding of the molecular underpinnings is only starting to emerge. Protein misfolding and aggregation is a common hallmark among these diseases, and produce a number of cellular and functional alterations. The loss of dopaminergic neurons in the substantia nigra justified the use of dopaminergic therapies in patients. However, these strategies do not appear to confer disease-modifying effects, and do not prevent progression. The idea that neurotrophic factors might promote cell survival is an attractive one. Existing evidence from clinical trials is currently inconclusive, but some patients display clear clinical benefits. Thus, the current challenge is to develop novel strategies that make the use of neurotrophic factors more consistent.
Export Options
About this article
Cite this article as:
Jose Diogenes Maria and Fleming Outeiro Tiago, Neurotrophic Factors as a Protective Strategy in Parkinsons Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237449
DOI https://dx.doi.org/10.2174/187152710793237449 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?
Current Alzheimer Research Editorial [Hot Topic:Role of Neural Stem Cells in Neurodegenerative Diseases:From the Molecule and Cell to the Clinic (Guest Editor: Oscar Gonzalez-Perez)]
Current Signal Transduction Therapy Review of Antibiotic and Non-Antibiotic Properties of Beta-lactam Molecules
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry HIV-1 Induced CNS Dysfunction: Current Overview and Research Priorities
Current HIV Research Role of Free Radicals and Poly(ADP-Ribose)Polymerase-1 in the Development of Spinal Cord Injury: New Potential Therapeutic Targets
Current Medicinal Chemistry Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets New Kid on the Block: Does Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis?
CNS & Neurological Disorders - Drug Targets Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders Novel Approaches for Potential Therapy of Cystic Fibrosis
Current Drug Targets Neuron-Microglia Interaction in Neuroinflammation
Current Protein & Peptide Science Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition
Current Gene Therapy Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules
Current Drug Targets Motor Neuron Disease and Acquired Axonal Neuropathy Association in HIV Infection: Case Report and Update
Current HIV Research Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration
Current Neuropharmacology Subject Index To Volume 6
Current Molecular Medicine Gene-Gene and Gene-Environment Interaction on the Risk of Parkinson’s Disease
Current Aging Science Role of Adenosine Receptors in Rare Neurodegenerative Diseases with Motor Symptoms
Current Protein & Peptide Science Novel Drug Delivery Systems for Releasing Growth Factors to the CNS: Focus on Alzheimer`s and Parkinson`s Diseases
Mini-Reviews in Medicinal Chemistry Therapeutic Approaches Targeting Pathological Tau Aggregates
Current Pharmaceutical Design